Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2020/08/027084
CTRI/2020/08/027084
Recruiting
未知

Study on Clinical Effects, Prolonged Safety and Efficacy of both Ayurveda combinations Bio-Immune as Anti-viral and Covalix Vaccoil as alternate to Vaccine of COVID-19 on exposed individuals and SARS2 nCoV contact - BICV19P

eaf BioLab Leaf Research Institute A Unit of Young Naturalist Network0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Sponsor
eaf BioLab Leaf Research Institute A Unit of Young Naturalist Network
Status
Recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
eaf BioLab Leaf Research Institute A Unit of Young Naturalist Network

Eligibility Criteria

Inclusion Criteria

  • •1\. Subjects must be divided into two major groups:
  • •A) Controlled Group
  • •B) Uncontrolled Group
  • •Control Group:
  • •Healthy Individuals
  • •Proven cases of SARS2 nCoV with or without other health issues like COPD, DM, HTN etc
  • •Uncontrolled Group:
  • •Asymptomatic patients who are not SARS2 nCoV positive, which can be either those who tested negative or normal public.

Exclusion Criteria

  • •1\. Patients who are taking radiation therapy
  • •2\. Patients with sepsis, HIV, Autoimmune
  • •3\. Patients on ventilator (critical SARS2 nCoV patients, who used any drug in treatment process)
  • •4\. Patients below age of 5 years
  • •5\. Patients with nerve disorder
  • •6\. History of receipt of blood transfusion or immunoglobulin products or expected receipt through the duration of the study
  • •7\. Known hepatic dysfunction including known or suspected active or chronic hepatitis infection
  • •8\. Clinically significant congenital anomaly of the respiratory tract
  • •9\. Inability to take oral medication
  • •10\.Prolonged QTc\-interval in baseline ECG ( \>500 ms)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 4
Clinical observation on the efficacy, safety and pharmacoeconomics of Guben Kechuan granule in treating chronic bronchitis
ITMCTR2200006560CHINA-JAPAN FRIENDSHIP HOSPITA
Not yet recruiting
Not Applicable
An evaluation study on the effectiveness and safety of thermal and massage device interventions on pain reduction and postural alignment in patients with low back paiDiseases of the musculoskeletal system and connective tissue
KCT0008212Korea University21
Completed
Not Applicable
Retrospective Clinical Study on Efficacy and Safety of Growing Rod Method for the treatment of Early Onset ScoliosisEarly Onset Scoliosis
JPRN-UMIN000032870Medtronic Sofamor Danek, Co.,Ltd.57
Completed
Not Applicable
A Clinical Study Evaluating the Safety and Effectiveness of the Ultrasound-guided Modified Thread Carpal Tunnel Release with Smartwire®; Pilot StudyDiseases of the nervous system
KCT0006013The Catholic University of Korea, Incheon St. Mary's Hospital15
Completed
Phase 2
Clinical research of safety and efficacy after a stop of dasatinib administration in patients with chronic myeloid leukemia -chronic phase (CML-CP) achieving a complete molecular response (CMR) on a treatment of tyrosine kinase inhibitors (TKIs).Chronic myeloid leukemia -chronic phase (CML-CP)
JPRN-UMIN000008583CML stem cell study group141